Amgen Raises Guidance After Better-Than-Expected First-Quarter Results
Amgen raised its guidance after better-than-expected first-quarter results, reporting total revenue of $8.6 billion, up 6% from a year earlier. GAAP earnings per share rose 4% to $3.34, while non-GAAP EPS increased 5% to $5.15.
The biotechnology company reported profit of $1.82 billion, with product sales up 4% in the quarter. Amgen also submitted a label update to the FDA on an autoimmune drug as it prepares for increasing competition in the coming years.
From the sources (4 posts)
@alphasenseinc$AMGN Earnings: - For the first quarter, total revenues increased 6% to $8.6 billion in comparison to the first quarter of 2025. - GAAP earnings per share (EPS) increased 4% from $3.20 to $3.34 for the first quarter, driven by higher opera
@businessAmgen raised its guidance after reporting better-than-expected first-quarter results, a sign of confidence as the biotechnology company prepares for increasing competition over the coming years
@wsjThe biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
@reutersAmgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug